NDAINTRA-ARTERIALPOWDER
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N7 position of guanine. It is active against both resting and rapidly dividing tumor cells.
Clinical Trials (1)
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Started Mar 2026
15 enrolled
Metastatic MelanomaLiver Metastases
Loss of Exclusivity
LOE Date
Sep 17, 2034
104 months away
Patent Expiry
Sep 17, 2034
Exclusivity Expiry
Aug 14, 2030